Another phase 1/2 study is under way in patients with triple-negative or HER2-negative breast cancer to assess a conjugate of the alpha emitter actinium-225 with an insulin-like growth factor-1 receptor-targeting humanized monoclonal antibody (ClinicalTrials.gov identifier NCT03746431). Here, IGF1R is linked to breast carcinoma.